EU approvals for olmesartan/amlodipine combo
This article was originally published in Scrip
Daiichi Sankyohas received approvals in Europe for Sevikar, a fixed-dose, single-pill combination of olmesartan and amlodipine. The once-daily therapy was filed in 28 EU countries in September 2007 and has been approved in Germany, the Netherlands, Spain, France, the UK and Belgium. Other markets are expected to follow soon.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.